Abstract

Background: This study evaluated the comparative efficacy of roxadustat for renal anemia between patients on maintenance hemodialysis (HD) and peritoneal dialysis (PD).
Materials and methods: 93 maintenance dialysis patients who regularly followed up from August 2015 to June 2021 were enrolled. Despite receiving a therapeutic dose ≥ 12,000 U/week of erythropoiesis-stimulating agents (E+SA) in the past 12 weeks, this had not worked very well. Subjects were assigned to the HD group (n = 60) or the PD group (n = 33) based on their dialysis treatment modality. All patients received oral roxadustat and were followed up for 24 weeks, after which their hemoglobin, serum iron, transferrin saturation, and ferritin were tested.
Results: We observed that the hemoglobin level of PD patients was significantly increased from 76.1 ± 15.7 g/L to 106 ± 23.8 g/L (p < 0 .001), while it significantly increased from 73.8 ± 12.9 g/L to 100.7 ± 20.2 g/L (p < 0.001) in the HD patients. After 1 and 3 months of roxadustat treatment, the hemoglobin level and its change in the PD group was significantly higher compared to that in the HD group despite the higher dose of roxadustat in the latter group. In addition, roxadustat was noted to reduce cholesterol levels and stabilize serum iron levels in parallel with improving hemoglobin levels.
Conclusion: Roxadustat can effectively increase the hemoglobin level of maintenance dialysis patients, even in those with low erythropoietin response or erythropoietin resistance, and, more importantly, its efficacy in PD patients was more significant.

*Contributed equally.

Author Details

Authors

• Liling Zhang¹*
• Yan Huang¹*
• Defeng Yin²
• Tingting Zhu¹
• Qi Liu¹
• Ying Li¹
• Linwang Gan¹

Departments

• ¹ Department of Nephrology,
• ² Department of Emergency, The Affiliated Hospital of Southwest Medical University, Luzhou, Sichuan Province, China

Address

Linwang Gan, MD
Department of Nephrology
the Affiliated Hospital of Southwest Medical University
No. 25 Taiping Street
Luzhou 646000, Sichuan Province, China
Email: [email protected]

Log in for Subscribers

Citation